|
Stallergenes is a global pharmaceutical company with leading innovation, provider of allergy solutions all around the world. Stallergenes has a comprehensive approach of the allergic diseases with a complete portfolio combining diagnosis products and treatments. Each year, almost 500,000 patients are treated with Stallergenes medicines. == Executive committee == *Christian CHAVY: Chief Executive Officer of Stallergenes. *Olivier de BEAUMONT: Senior Vice President, Global Medical Affairs. *Peter BUHLER: Chief Financial Officer. *Alfonso CAMBA BARBOLLA: Senior Vice President, Technical Operations. *Ivan COHEN-TANUGI: Senior Vice President, International Operations. *Thomas LANG: President of Stallergenes Inc., Stallergenes’ US subsidiary. *Jérôme TILLY: Senior Vice President, Human Resources. *Philippe MOINGEON: Senior Vice President, Research and Pharmaceutical Development. *Dominique PEZZIARDI: Senior Vice President, Strategic Marketing and Global Market Access. *Denis RIGOLET: Senior Vice President, Quality Assurance. *Poul SORENSEN: Senior Vice President, Strategic Development. *Cyril TAVIER: Senior Vice President, Southern Europe Operations. *Robert K. ZELDIN: Senior Vice President, Global Clinical Development. 抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Stallergenes」の詳細全文を読む スポンサード リンク
|